$3.84
3.39% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US8883143096
Symbol
TTNP
Sector
Industry

Titan Pharmaceuticals, Inc. Stock price

$3.84
-0.02 0.47% 1M
-2.58 40.23% 6M
-4.41 53.51% YTD
-2.96 43.59% 1Y
-25.16 86.77% 3Y
-85.50 95.71% 5Y
-574,394.16 100.00% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.13 3.39%
ISIN
US8883143096
Symbol
TTNP
Sector
Industry

Key metrics

Market capitalization $3.51m
Enterprise Value $-580.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.09
P/B ratio (TTM) P/B ratio 0.88
Revenue growth (TTM) Revenue growth -98.99%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-7.13m
Free Cash Flow (TTM) Free Cash Flow $-6.76m
Cash position $4.09m
EPS (TTM) EPS $-6.50
Short interest 1.36%
Show more

Is Titan Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Financial data from Titan Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.04 0.04
78% 78%
-
-0.03 -0.03
114% 114%
-
- Selling and Administrative Expenses 6.15 6.15
18% 18%
-
- Research and Development Expense 0.91 0.91
73% 73%
-
-7.09 -7.09
15% 15%
-
- Depreciation and Amortization 0.04 0.04
78% 78%
-
EBIT (Operating Income) EBIT -7.13 -7.13
17% 17%
-
Net Profit -5.46 -5.46
36% 36%
-

In millions USD.

Don't miss a Thing! We will send you all news about Titan Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Titan Pharmaceuticals, Inc. Stock News

Neutral
PRNewsWire
3 months ago
MILWAUKEE , Aug. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Titan (NASDAQ: TTNP) for possible breaches of fiduciary duty and other violations of law in its transaction with KE Sdn. Bhd. Click here to learn how to join our investigation https://www.ademilaw.com/case/titan-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.
Neutral
Business Wire
3 months ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) and KE Sdn. Bhd. is fair to Titan shareholders. Upon closing of the proposed transaction, Titan shareholders expect to own approximately 13.3% of the combined company. Halper Sadeh encourages Titan shareholders to click here to learn more ab...
Neutral
GlobeNewsWire
3 months ago
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the “Merger Agreement”) regarding a business combination with KE Sdn. Bhd. (“KE”). The Merger Agreement was approved by Titan's board of directors (the “Board”). If the Merger Agreement is approved by th...

Company Profile

Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. Its lead product is Probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.

Head office United States
CEO Brynner Chiam
Employees 4
Founded 1992
Website www.titanpharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today